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Introduction: Diabetic nephropathy that means albuminuria greater than 30 mg/day, affects about one
third of diabetic patients. There are many studies about the effect of different medications for diabetic
nephropathy with controversy in their results. So, the aim of the study was to investigate the effect of
pioglitazone on decreasing of proteinuria in type II diabetic patients and nephropathy.
Methods and materials: It is a double blind clinical trial. At ﬁrst, 2356 medical carts of the patients were
evaluated and 76 patients with type 2 diabetes mellitus with proteinuria greater than 250 mg / day were
enrolled in 2 equal groups. In the case group, pioglitazone 15 mg/day was prescribed and patients in the
control group received placebo for two months. At the beginning of the study and after 2 months, urinary
protein during 24 h was measured in all of the patients and data were entered to SPSS (version23) and
evaluated by using Chi- square, Mc Nemar, paired t-test and logistic regression model.
Results: At the beginning of the study, urine protein during 24 h in the case and control groups were
957.7  385.1 and 972.1  378.6 respectively (P = .872). So, after 2 months the mean proteinuria in the
case and control groups were 647.3  367.2 and 896  372.4 respectively that is valuable (P = 0.005).
Pioglitazone had the considerable effect on FBS,HbA1c and blood triglyceride too.
Conclusion: The study showed that low dose of pioglitazone is an effective, safe and inexpensive method
in reducing of proteinuria in type2 diabetic patients with nephropathy.
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Type 2 diabetes is a type of the metabolic disorder that is
recognized with high levels of glucose in the blood which is due to
a resistance status against insulin and relative insulin deﬁciency.
Type 2 diabetes is recognized by three pathophysiologic
abnormalities: insulin secretion, insulin resistance, and excessive
glucose production by the liver. Diabetes is common in both
developed and developing countries. Obesity is common in type 2
diabetes mellitus. The rate of diabetes has risen dramatically over
the 50 years ago as obesity has increased. Over the two decades
ago, the global prevalence of diabetes has increased from an
estimated 30 million in 1985 to 382 million in 2013. 90% of
individuals with diabetes suffer from type 2 diabetes, and 10% have
type 1 diabetes mellitus and gestational diabetes, respectively. The
cause of resulting type 2 diabetes is related to lifestyles and genetic
factors. Some factors related to life style such as lack of physical$ Authors declare this paper has not submitted anywhere for publish.
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over, nutritional factors increase the risk of developing type 2
diabetes. Most people with type 2 diabetes have had a strong
genetic basis, and Its incidence is among identical twins between
70% and 90%. Recent studies have revealed the role of more than
70 genes for the appearance of this disease. Diabetes is one of the
main causes of mortality. In the United States, diabetes was
reported as the seventh major cause of death in 2010. It has been
shown in one of recent estimates that 8% of mortality caused by
diabetes disease in 2013 in all over the world.
life expectancy has decreased in type 2 diabetes, because of
cardiovascular and renal diseases. In developed countries, type 2
diabetes is the major cause of blindness and renal failure. In
addition, the risk of mental impairment and dementia is increased
by involving cerebrovascular accidents. Diabetic nephropathy
illustrates with a progressive increase in protein excretion
(proteinuria), which is observed in prolonged diabetes, decrease
renal function and ultimately led to renal failure. Type II diabetes
mellitus is the most important factor of chronic renal failure,
followed by ﬁnal stage of renal failure that causes death in diabetic
patients. About 40% of End Stage Renal Disease(ESRD) was due to
diabetes leaded to spend more than $ 4 billion per year in the
Table 1
Mean of pretest variables in the intervention and control groups.
Group Case Control P-value
Variables Mean  SD Mean  SD
Age(year) 63.8  3.9 61.7  3.3 0.012
Duration of diabetes mellitus (year) 11.8  1.8 11.5  2.7 0.526
Glomerular ﬁltration rate 66.9  8.5 68.3  8.6 0.490
Blood pressure Systolic (mmHg) 134.9  8.7 131.7  8.4 0.114
Blood pressure Diastolic (mmHg) 80.9  8.9 82  6.3 0.530
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less percentage of patients with type 2 diabetes eventually develop
ESRD. Of course, because of the higher prevalence of type 2
diabetes, the number of cases of type II diabetes is higher. Although
infections and inﬂammatory diseases such as types of glomerulo-
nephritis in the past were the most common causes of ESRD,
diabetes and high blood pressure are now the most common
causes of this disease [1].
The primary evidence of nephropathy shows the existence of
very low levels of albumin in the urine (30 mg/day), called
microalbuminuria and the microalbuminuria patient is considered
as primary nephropathy. Then microalbuminuria may progress to
macroalbuminuria (higher than 300 mg/day) or severe nephropa-
thy. When severe proteinuria is observed, a continuous decrease in
glomerular ﬁltration rate will occur. Hypertension is commonly
associated with albuminuria and nephropathy [2].
The main mechanism for diabetic nephropathy is not clear, but
several risk factors involve. One of the serious risk factors for
nephropathy in diabetic patients is hypertension. The other factor
is high hemoglobin glycosylated (higher than 9%) mentioned as
increasing risk factor of nephropathy. Diabetic patients with
obesity and overweight are also at risk for nephropathy based on
Body Mass Index (BMI). Also, the duration of diabetes and the age
of the patient predict the progression of nephropathy [1]. In a
study, glycosylated hemoglobin, smoking, the duration of diabetes,
systolic blood pressure and diastolic blood pressure showed a
signiﬁcant relationship for nephropathy [2].
Hyperglycemia makes injury to arteries by several complex
mechanisms. Inﬂammatory cytokines produced by inﬂammatory
cells cause damage to the renal cells and accelerate changing
epithelial cells to mesenchymal cells and increase extracellular
matrix. Immunological and inﬂammatory mechanisms play an
important role in the progression of diabetic nephropathy by
activating immune cells and increasing the production of
inﬂammatory molecules. The exact control of blood glucose and
blood pressure can decrease the progression of the disease in the
initial stages of kidney involvement in patients with diabetes and
especially when protein excretion is still in low level, and even it is
possible to improve this condition. In more advanced stages,
protein excretion is more. However, blood glucose control,
consumption restriction, and blood pressure control are effective
in decreasing the process of the disease, but it does not stop the
trend of the disease. Currently, diabetic nephropathy is treated
with ACE inhibitors or angiotensin receptor blockers(ARBs) in
addition to blood glucose reducing drugs. Also, limited diets of
protein and sodium are used, nevertheless, the prevalence of
diabetic nephropathy and diabetes-induced renal failure is still at
the high level.
By reducing proteinuria, progression of renal damage to ESRD
will be slowed. So, it will improve patients' life and decrease
morbidity and costs of end- stage renal disease. Such studies are
necessary for achieving these purposes.
2. Materials and methods
The present study was done in the year 2017 with clinical trial
code IRCT2017080210222N10. This is a double-blind, randomized
clinical trial (prescribing person and also patients who received the
drugs (placebo or pioglitazone) were not aware of these two
consumed drug types. The variable of research was urine protein
excretion rate in 24 h. At ﬁrst, written informed consent was
obtained from the patients and the research objectives were
explained to them. Patients were assured that their information
would remain as a secret and they are not shared with any
individual or group. Patients were examined by a nephrologist. The
population under study was 2356 cases of patients, documents inthe Nephrology ward of Imam Ali Clinic, Shahrekord. Inclusion
criteria were: type 2 diabetic patients, 24-h urine protein more
than 250 mg/day, without hypothyroidism and heart failure,
HbA1C less than 8, blood pressure less than 160/100, creatinine
lower than 2 or GFR greater than 50, and exclusion criteria was
undesirable cooperation during the study, and considerable drug
side effects. Sample size and sampling of patients referred to Imam
Ali Hospital with type 2 diabetes, who had inclusion criteria was 76
patients in the study, 38 patients in each group.
76 patients with type 2 diabetes mellitus with 24-hour urine
protein >250 mg/day were selected and then they were divided
into two groups, including the group receiving pioglitazone 15 mg
daily and the placebo group for two months with stratiﬁed
randomization that is they were identical in terms of proteinuria
rates (three groups of proteinuria (less than 600 mg, 600–1200 mg
and 1201 mg and above), During the study, one patient in the
pioglitazone group and two in the placebo group due to lack of
proper cooperation were excluded. 24-h urine protein was
determined before intervention and 2 months later. The results
were recorded in the checklist and analyzed by statistical tests.
Data entered in the SPSS software (version23) and analyzed using
descriptive statistics, Chi- square, Mc Nemar, paired t-test and
logistic regression model.
3. Results
In this study, the following results were obtained by comparing
the effect of pioglitazone on proteinuria in patients with type 2
diabetes with nephropathy in Imam Ali Clinic, Shahrekord. A total
of 73 diabetic patients with type II diabetic nephropathy (37 cases
and 36 controls) participated in the current study. The age range of
the patients was between 54–71 years with a mean of 62.8  3.8.
35 patients (47.9%) were female and the rest were male. No
difference was observed based on sex in the two groups (P = 0.73).
Duration of diabetes mellitus, glomerular ﬁltration rate (GFR),
systolic and diastolic blood pressure had no valuable difference in
the case and control groups The quantitative characteristics of
patients in two groups were summarized in Table 1. It showed that
the two groups were identical except for age.
The mean of glomerular ﬁltration rate was 66.9  8.5 in the case
group and 68.3  8.6 in the control group.
Systolic blood pressure in the case group was 134.9  8.7 and in
the control group was 131.7  8.4. Diastolic blood pressure in the
intervention group was 80.9  8.9 and in the placebo group was
82  6.3.
Patients’ consumed drugs in two groups during the study
displayed in Table 2.
Consumption of ACE/ARB, statins, oral hypoglycemic drugs,
diltiazem and insulin was compared in the case and control groups.
In terms of ACE / ARB consumption, in the ﬁrst group (intervention
group), 94.6% (35 patients) used drug, and 5.4% (2 patients) did not
use the drug, and in the second group (placebo), 97.2% (35 patients)
had drug use, And 2.8% (1 people) didn't use drug.
Regarding the use of statin in the intervention group, 91.9% (34
patients) use drugs and 8.1% (3 non-drug users) and in the placebo
Table 2
Patients’ consumed drugs in two groups during the study.
Group Case Control P-value
Consumed drugs Frequency Percent Frequency Percent
ACE/ARB 35 94.6 35 97.2 1
Statin 34 91.9 33 91.7 1
Oral hypoglycemic drugs 36 97.3 34 94.4 0.615
Diltiazem 10 27 12 33.3 0.557
Insulin 3 8.1 3 8.3 1
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use.
In terms of oral hypoglycemic agents, in the case group 2.7% (1
patients) did not use drugs, 97.3% (36 people) used the drug, and in
the control group, 5.6% (2 patients) didn't use, and 94.4% (34
patients) had drug usage.
Regarding the use of diltiazem in the case group, 73% (27
patients) did not use the drug and 27% (10 patients) used the drug,
and in the control group, 66.7% (24 patients) did not take drugs and
33.3 Percentage (12 people) took medication.
In the case group, 8.1% (3 patients) used insulin and 91.9% (34
patients) didn't use insulin, and in the control group 8.3% (3
patients) used insulin and 91.7% (33 patients) did not use the drug.
With regard to the meaningful view, there is no difference in
patients’ consumed drugs in these two groups.
The amount of measured parameters before and after
intervention in two groups included in Table 3. Body mass index
(BMI) was 28.03  2.08 in the ﬁrst group (receiving pioglitazone)
and 27.67  2.06 in the control group (placebo) ranged from 24 to
33. Regarding the biochemical parameters, there was a signiﬁcant
decrease in 24hr urine protein in the case group compared to the
control group. This means that there was no signiﬁcant difference
between the two groups before the intervention, but after the
intervention, this difference was signiﬁcant (p = 0.005). The resultsTable 3
The average amount of studied parameters before and after the intervention and its ch
parameter Group 
Proteinuria(mg/d) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
FBS(mg/dl) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
BS -2 hr PP(mg/dl) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
HbA1c(%) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
Triglyceride(mg/dl) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
LDL(mg/dl) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
BMI(kg/m2) Pretest 
Posttest 
Signiﬁcant rate of pretest and posttest 
Difference of pretest and posttest 
a Probability values are corrected for age(logistic regression model).indicated that the average 24-hour urine protein level at the
beginning of the study and before the onset of the intervention
(receiving the drug) was 957.7  385.1 mg/d, which after the
intervention and consuming pioglitazone within two months the
24hr urine protein reached to 647.3  367.2 mg/d. Mean HbA1C
had a signiﬁcant difference before and after the intervention
(p < 0.001). The mean before the study was 7.38  0.32 and after
the intervention was 7.01  0.22, which was higher than the
control group but there was no signiﬁcant difference in HbA1C
before and after intervention in the control group. FBS had a
signiﬁcant difference before and after the intervention (p < 0.001)
in the case group. The mean before the study was 125.41 16.52
and after the intervention was 110.62  14.5, which was higher
than the control group but there was no signiﬁcant difference in
FBS before and after intervention in the control group.
Two-hour post prandial blood sugar (2hrppBS) and LDL had no
valuable difference in the case and control groups after interven-
tion(p = 0.149 and p = 0.228 respectively).
Triglyceride level reached from 164.3  48.2 to 138.4  14.07
after intervention in the case group (p < 0.001), but in the control
group it decreased from 156.1  42.4 to 154.9  40.08 (p = 0.515)
and signiﬁcant difference is between these two groups after
intervention(P < 0.001).
The abundance of proteinuria level based on the level of
proteinuria reported before and after the study in two groups in
Table 4.
We observed after the intervention, the reduction level of
proteinuria was more in the intervention group. The McNemar test
showed these changes that there was a decrease in the proteinuria
level in both groups (P < 0.01)
4. Discussion
Diabetic nephropathy is a major microvascular complication in
long-standing diabetic patients who eventually undergo renalanges in two groups.
Case Control P-value
Mean  SD Mean  SD
957.7  385.1 972.1  378.6 0.872
647.3  367.2 896  372.4 0.005
<0.001 0.011 –
310.5  112 76.2  170.9 <0.001a
125.41  16.52 122.92  12.85 0.476
110.62  14.5 122  10.24 <0.001
<0.001 0.542 –
14.8  7.9 0.92  8.9 <0.001a
145.1  14.3 142.4  8.8 0.33
142.3  13.03 142.3  8.82 0.994
<0.001 0.898 –
2.8  4.4 0.16  7.74 0.149a
7.38  0.32 7.36  0.28 0.694
7.01  0.22 7.36  0.27 <0.001
<0.001 0.856 –
0.37  0.14 0.002  0.09 <0.001
164.3  48.2 156.1  42.4 0.445
138.4  14.07 154.9  40.08 0.089
<0.001 0.515 –
25.9  11.2 1.2  11.1 <0.001a
98.03  15.6 98.9  16.3 0.818
97  12.32 100.66  16.77 0.289
0.531 0.352 –
1.05  10.15 1.78  11.3 0.228a
28.03  2.08 27.52  2 0.301
28.03  2.08 27.67  2.06 0.454
0.324 <0.001 –
0.005  0.032 0.14  0.099 <0.001a
Table 4
Abundance of proteinuria level during the study in two groups based on level of proteinuria.
Group Case Control P-value
Stage Frequency Percent Frequency Percent
Pretest Less or equal of 600 10 27 9 25 0.981
Between 601-1200 17 46 17 47.2
Equal and higher than 1201 10 27 10 27.8
Posttest Less or equal of 600 22 59.5 8 22.2 0.005
Between 601-1200 10 27 20 55.6
Equal and higher than 1201 5 13.5 8 22.2
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(A1c < 7%), treating hypertension (<130/80 mmHg or <125/
75 mmHg if proteinuria >1.0 g/24 h and increased serum creati-
nine), using drugs with blockade effect on the renin-angiotensin-
aldosterone system, and treating dyslipidemia (LDL cholesterol
<100 mg/dl) are effective strategies for preventing the develop-
ment of microalbuminuria, in delaying the progression to more
advanced stages of nephropathy and in reducing cardiovascular
mortality in patients with type 1 and type 2 diabetes [1]. To
prevent development of this disease and to improve advanced
kidney injury, effective therapies directed toward the key
molecular target are required. Metabolic and hemodynamic
alterations have been considered as the classical factors involved
in the development of renal injury in patients with diabetes
mellitus. However, the exact pathogenic mechanisms and the
molecular events of diabetic nephropathy remain incompletely
understood. Nowadays, there are convincing data that relate the
diabetes inﬂammatory component with the development of renal
disease [7].
Three subtypes of the PPAR nuclear fatty acid receptors have
been identiﬁed: alpha, beta/delta and gamma. PPAR alpha is
believed to participate in fatty acid uptake (beta- and omega-
oxidation) mainly in the liver and heart. PPAR beta/delta is involved
in fatty acid oxidation in muscle. PPAR gamma is highly expressed
in fat to facilitate glucose and lipid uptake, stimulate glucose
oxidation, decrease free fatty acid level and ameliorate insulin
resistance. Synthetic ligands for PPAR alpha and gamma such as
ﬁbric acid, and thiazolidinediones have been used in patients with
type 2 diabetes and pre-diabetic insulin resistance with signiﬁ-
cantly improved HbA1c and glucose levels. In addition, non-
hypoglycemic effects may be elicited by PPAR agonists or dual
agonists including improved lipid metabolism, blood pressure
control and endothelial function, as well as suppressed athero-
sclerotic plaque formation and coagulation. However, issues of
safety and clinical indication remain undetermined for use of PPAR
agonists for the incidence of heart disease in metabolic syndrome
and type 2 diabetes [10]. In Brun RP and et al. study, data strongly
suggest that PPAR gamma is the predominant receptor regulating
adipogenesis; however, they also suggest that PPAR alpha may play
a role in differentiation of certain adipose depots in response to a
different set of physiologic activators or in certain disease states
[8]. In Ko GJ et al study, they investigated the effect and molecular
mechanism of the PPAR gamma agonist, pioglitazone, on the
progression of diabetic nephropathy in type 2 diabetic rats. It
reaveled that pioglitazone not only improves insulin resistance,
glycemic control and lipid proﬁle, but also ameliorates renal injury
through an anti-inﬂammatory mechanism in type 2 diabetic rats
[16]. There are some evidence that thiazolidinediones had a direct
effect on the kidneys through the activation of PPAR receptors
identiﬁed in the kidneys. The animal studies conducted by Ma et al.
[20] and Haraguchi et al. [19], Jin et al [15] have also mentioned the
effects. Katavetin et al. [12] reported a signiﬁcant decrease in the
mean of the urinary protein excretion from 1.64 to 0.98 g/day, that
is similar to this study and no signiﬁcant difference in the bloodglucose control and blood pressure in both treatment and control
groups. In another study by Agarwal et al., it was found that there
was a signiﬁcant decrease in the proteinuria level in the
pioglitazone group [13].
The accumulation of advanced glycosylated end-products
(AGEs), the activation of isoform(s) of protein kinase C (PKC)
and the acceleration of the aldose reductase pathway may explain
how hyperglycemia damages tissue. PKC is one of the key signaling
molecules in the induction of the vascular pathology of diabetes. A
number of gene loci have been investigated to try to explain the
genetic susceptibility to diabetic nephropathy [4]. Advanced
glycation end products (AGEs) have been implicated in the
pathogenesis of diabetic kidney disease [8]. In Myint KM study,
they examined whether inhibition of the receptor for advanced
glycation end products (RAGE) could attenuate changes in the
diabetic kidney. Inactivation of the RAGE gene in a mouse model of
diabetic nephropathy results in signiﬁcant suppression of kidney
changes, including kidney enlargement, increased glomerular cell
number, mesangial expansion, advanced glomerulosclerosis,
increased albuminuria, and increased serum creatinine compared
with wild-type diabetic mice [5].
The efﬁcacy of renin-angiotensin system (RAS) blockers on type
2 diabetes studied by Fukuda M. This study was undertaken to test
the hypothesis that candesartan may enhance the protective
effects of pioglitazone against type 2 diabetes. Their work
demonstrated that candesartan signiﬁcantly potentiated the
protective effects of pioglitazone against cardiorenal and vascular
injury, and diabetes in obese type 2 diabetic mice. Thus, the
combination of pioglitazone with candesartan is potentially a
promising therapeutic strategy for type 2 diabetes [14]. Angioten-
sin-converting enzyme (ACE) is a key regulator of the renin-
angiotensin system (RAS). ACE2 is a newly described enzyme
identiﬁed in rodents and humans with a more restricted
distribution than ACE, and is found mainly in heart and kidney.
ACE2 might act in a counter-regulatory manner to ACE, modulating
the balance between vasoconstrictors and vasodilators within the
heart and kidney, and playing a signiﬁcant role in regulating
cardiovascular and renal function [5]. It was revealed that
pioglitazone reduces pro-inﬂammatory markers in patients with
overt diabetic nephropathy, which indicates potentially beneﬁcial
effects on overall cardiovascular risk. This surrogate endpoint
needs to be conﬁrmed in trials designed to demonstrate
cardiovascular protection [14]. Tanimoto M, showed that the
effect of pioglitazone on microalbuminuria might not be due to
changing systemic blood pressure and blood glucose levels. It
appears that the decrease of urinary albumin excretion might be
related to improvement of glomerular enlargement, including
hyperﬁltration, since the levels of endothelial constitutive nitric
oxide synthase (ecNOS) protein were reduced by pioglitazone in
the glomerular vessels [17]. In a study by Abe et al in 2007 about
the efﬁcacy of pioglitazone in the controlling blood glucose in 20
dialysis patients, patients were treated with 15 mg pioglitazone in
the ﬁrst 4 weeks with a meal in the morning. If the unwanted
effects of the drug do not appear, the dosage of the drug can be
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signiﬁcantly effective in reducing HbA1c, triglyceride and systolic
and diastolic blood pressure [9].
A reduction of proteinuria in patients with the non-diabetic
renal disease was observed during the 4-month treatment with
pioglitazone which continued for 2 months after the cessation of
the treatment was shown in Shahidi S et al. study. However, 4
months after the cessation of the treatment, a little increase was
detected in the level of proteinuria [18]. In this study, the group
consumed pioglitazone, their urine protein levels decreased
signiﬁcantly compared to the beginning of the trial.
In the current study regarding p-value of less than 0.001, it
indicated a positive effect of the drug on the reduction of urine
protein. The results of t-test showed that there was a signiﬁcant
decrease in HbA1c, FBS and triglyceride in the case group after
intervention but with no considerable effect on LDL, 2hrppBS and
BMI. Therefore, the initiation of drug use at lower proteinuria
levels will be associated with an increased chance of treatment.
Due to the young nature of these studies on the effect of
tiazolidinedione drugs family on reducing proteinuria of patients
with type 2 diabetes and nephropathy, consideration of the
problems and limitations of these studies may play an important
role in the continuation of the pathway of researchers. Although
there is no speciﬁc complication in this study, since the possibility
of heart or liver complications with this drug alone and in
combination with other common drugs has not yet been
addressed, studies are needed to evaluate the tolerable side
effects in these patients.
5. Conclusion
Based on the results of this study, the use of pioglitazone was
effective in decreasing the level of urine protein in patients with
type 2 diabetes and nephropathy for two months and no side
effects were observed using this drug. It is suggested to evaluate
the beneﬁts and side effects of taking pioglitazone in Diabetic
Nephropathy, a similar study should be conducted over a longer
period of time.
Limitations of research
Failure to follow up and not referring again patients were
problems and limitations of the study. If samples were dropped,
new samples were selected according to the criteria for entering
and leaving the study and were included in the study.
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